Journal Mobile Options
Table of Contents
Vol. 24, No. 1, 2007
Issue release date: June 2007
Section title: Review
Cerebrovasc Dis 2007;24:1–10
(DOI:10.1159/000103110)

Symptomatic Intracerebral Hemorrhage following Thrombolytic Therapy for Acute Ischemic Stroke: A Review of the Risk Factors

Lansberg M.G. · Albers G.W. · Wijman C.A.C.
Stanford University, Stanford Stroke Center, Palo Alto, Calif., USA
email Corresponding Author

Abstract

Background: Symptomatic intracerebral hemorrhage (SICH) following thrombolytic therapy for acute ischemic stroke is associated with a high rate of morbidity and mortality. Knowledge of the risk factors associated with SICH following thrombolyitc therapy may provide insight into the pathophysiological mechanisms underlying the development of SICH, lead to the development of treatments that reduce the risk of SICH and have implications for the design of future stroke trials. Methods: Relevant studies were identified through a search in Pubmed. Included studies used multivariate analyses to identify independent risk factors for SICH following thrombolytic therapy. For each variable that was found to have a significant association with SICH, a secondary literature search was conducted to identify additional reports on the specific relationship between that variable and SICH. Summary of Review: Twelve studies met inclusion criteria for the systematic review. Extent of hypoattenuated brain parenchyma on pretreatment CT and elevated serum glucose or history of diabetes were independent risk factors for thrombolysis-associated SICH in six of the twelve studies. Symptom severity was an independent risk factor in three of the studies and advanced age, increased time to treatment, high systolic blood pressure, low platelets, history of congestive heart failure and low plasminogen activator inhibitor levels were found to be independent risk factors for SICH in a single study. Although these data should not alter the current guidelines for the use of rt-PA in acute stroke, they may help develop future strategies aimed at reducing the rate of thrombolysis-associated SICH.

© 2007 S. Karger AG, Basel


  

Key Words

  • Ischemic stroke
  • Hemorrhagic transformation
  • Plasminogen activator
  • Intracerebral hemorrhage
  • Thrombolytic therapy

Introduction


Thrombolytic therapy is the only available medical treatment for acute ischemic stroke that has been proven to be effective. Intravenously administered recombinant tissue plasminogen activator (rt-PA) has been shown to improve the long-term functional outcome [1, 2] and is recommended for the treatment of eligible acute stroke patients [3,4,5]. However, the use of thrombolytic therapy is associated with an increased risk of symptomatic intracerebral hemorrhage (SICH).

The risk of SICH in stroke patients treated with rt-PA is approximately 6%. In a recent pooled analysis of 6 randomized trials of intravenous rt-PA for stroke the rate of substantial intracerebral hemorrhage was 5.9% in patients treated with rt-PA compared with 1.1% in placebo patients [6]. A meta-analysis of safety data from 15 open-label studies of intravenous rt-PA including 2,639 ischemic stroke patients reported an SICH rate of 5.2% [7]. SICH following thrombolytic therapy is associated with very poor clinical outcomes. The fatality rate is between 50 and 80% and the rate of severe morbidity or mortality exceeds 90% [6,8,9,10]. What proportion of poor outcomes is attributable to SICH is, however, not known because there is overlap between risk factors for thrombolysis-associated SICH and risk factors for poor outcome following thrombolytic therapy in the absence of SICH.

Many studies have reported on clinical, radiological and laboratory variables that are associated with an increased risk of SICH following thrombolytic therapy, but rigorous systematic reviews of these studies are sparse. The aim of this report is to summarize this extensive body of literature and to provide a comprehensive overview of the variables that are likely to be independent predictors of SICH following thrombolytic therapy. It is important to note that this systematic review does not address the efficacy of rt-PA treatment in stroke patients at increased risk for thrombolysis-associated SICH and that these patients may still benefit from treatment. A better understanding of thrombolysis-associated risk factors may, however, provide insight into the pathophysiology of intracerebral hemorrhage following administration of thrombolytics, lead to the development of treatment strategies aimed at reducing SICH risk and help design future clinical trials.

 

Methods


Potentially relevant studies were identified by conducting a Medline/Pubmed search on August 1, 2006, using the following key words: ‘intracerebral’, ‘hemorrhage’, ‘stroke’ and ‘thrombolytic’. The query was limited to human studies published in the English literature. The reference list of all relevant articles and the authors’ personal libraries were reviewed to identify additional studies. Only studies that used multivariate analysis to identify independent risk factors of SICH associated with thrombolytic therapy for stroke were included. Inclusion of each study was determined by consensus among all authors. We accepted the definitions of SICH used by the authors in each study, although these definitions varied among studies (table 1). Variables that were independently associated with an increased risk of SICH following thrombolysis were abstracted from the literature. For each variable that was found to have a significant association with SICH in 1 of the multivariate analyses, a secondary broader literature search was conducted to identify additional articles addressing the relationship between that variable and the occurrence of thrombolysis-associated SICH. A broader literature review is also presented for 2 select variable categories (antiplatelet use and MRI characteristics) that have received considerable attention in the scientific literature but that have not been shown to have an independent association with SICH in multivariate analyses.

TAB01
Table 1. Overview of studies

Summary of Review

The Pubmed query identified 635 articles, of which 11 were included in this systematic review. One additional article that met inclusion criteria was identified through review of reference lists and the authors’ libraries [9]. Therefore, the prespecified search strategy resulted in 12 articles that met the inclusion criteria for this systematic review [8,9,10,11,12,13,14,15,16,17,18,19]. Table 1 provides an overview of these studies. Table 2 lists the independent risk factors for SICH identified by these studies.

TAB02
Table 2. Risk factors for SICH after thrombolysis

CT Characteristics

Early ischemic changes (EICs) were independently associated with an increased risk of SICH in 6 of the 12 studies [8, 10,12,13,14, 16]. Consequently, there is strong evidence to support an association between the presence of EICs on CT and thrombolysis-associated SICH. EICs on CT include hypoattenuation (hypodensity) of brain parenchyma, hypodensity of cortex (loss of grey-white differentiation) and swelling of the cerebral parenchyma (effacement of sulci and/or compression of ventricle) [20].

When the definition of EICs is considered, it appears that the extent of EICs, particularly the volume of hypodense brain tissue, is an important factor in determining the risk of SICH. Several studies quantified the degree of early infarct signs according to various scales [9,10,11,13,14,15,16,17,18]. For example, the Alberta Stroke Programme Early CT Score (ASPECTS) [13] quantifies EICs. Two studies have shown that in patients treated with intravenous rt-PA, lower ASPECTS scores are associated with an increased risk of SICH [13, 21]. Similarly, studies that have quantified the degree of CT changes as involving less or more than 33% of the middle cerebral artery (MCA) territory have found higher SICH rates in patients with more extensive early infarct signs [10, 16]. Specifically, Tanne et al. [10 ] reported a 3-fold increased risk of SICH in patients with early infarct signs involving ≤⅓ of the MCA territory and a 6-fold increased risk when involving >⅓ of the MCA territory compared to patients without early infarct signs. Further evidence stressing the importance of quantifying the extent of early infarct signs stems from the results of the European Cooperative Acute Stroke Study (ECASS I) [22]. In this study an increase in fatal intracerebral hemorrhages was found with increasing extent of early infarct signs in patients treated with rt-PA [23]. A possible limitation of the use of EICs as a predictor of SICH risk is the lack of agreement among physicians in categorizing early CT changes [13,23,24,25,26,27,28]. A second limitation is that all reported studies are based on CT scans which were obtained several years ago. Because CT technology improves continuously, the results of these studies may not be entirely applicable to scans obtained with today’s state-of-the-art CT technology.

Serum Glucose Levels or History of Diabetes Mellitus

A history of diabetes, baseline serum glucose or both variables were assessed in each of the 12 included studies and were independently associated with an increased risk of SICH in 6 [9,10,11,12,13, 15]. In univariate analysis baseline serum glucose showed a significant association with SICH in 6 of 8 studies for which the results of this analysis were reported [8,9,10,11,13,14,15, 19]. In contrast, univariate analysis between history of diabetes and SICH was significant in only 3 [10,11,12] of 6 studies that reported on this relationship [8,10,11,12, 15, 29]. Out of 4 studies that reported the univariate analysis for both serum glucose and history of diabetes, 2 reported significant associations between both risk factors and SICH [10, 11] and 2 only showed a significant association between serum glucose and SICH [8, 15]. These results suggest that elevated serum glucose on admission or a history of diabetes mellitus places a patient at increased risk for SICH following rt-PA.

Symptom Severity

In 3 studies greater symptom severity, as assessed by the National Institutes of Health Stroke Scale (NIHSS), was independently associated with SICH [8, 14, 19]. In the Multicenter Acute Stroke Trial-Europe study the interaction between decreased level of consciousness and streptokinase treatment was associated with an increased risk of SICH [12]. As symptom severity correlates with infarct volume [30], the association between symptom severity and SICH is consistent with the notion that SICH is most likely to occur in the setting of extensive and severe cerebral ischemia. The lack of an independent association between symptom severity and SICH in most of the evaluated studies may be explained by masking of this association by other variables. Specifically, NIHSS score is significantly associated with EICs on CT [31].

Age

Advancing age was found to be an independent risk factor of SICH in 1 of the included studies [16]. In 3 other studies advancing age was associated with SICH in univariate analysis but did not remain significant after other variables were added to the model [8, 10, 19]. However, in multivariate analyses of risk factors for hemorrhage in the pooled analysis of the NINDS, ECASS and Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) trials, age was associated with the occurrence of substantial parenchymal hematoma [6]. This discrepancy may be the result of differences between the statistical models used for the pooled analysis and those used for the studies included in this review. For example, the pooled analysis had greater power to detect predictors because of a larger sample size. It also used a different outcome variable (substantial parenchymal hematoma instead of SICH) and evaluated different dependent variables (e.g. early CT infarct changes were not included).

Because most studies excluded patients above age 80, the risk of SICH in this population has not been well studied. However, in the Canadian Alteplase for Stroke Effectiveness Study study, which was included in this review, and 1 additional study which did not meet inclusion criteria for this review, the rate of SICH in rt-PA-treated patients older than 80 years was not different from patients younger than 80 [32, 33]. Moreover, in the NINDS tPA trial, which had no upper age limit in the latter part of the study, no association between age and SICH was found. A recent systematic review that compared stroke outcome after rt-PA in older versus younger patients also found no increased risk of SICH with advancing age [34]. These data suggest that acute stroke patients above 80 should not be excluded from treatment with tPA based on their SICH risk. In contrast, advanced age has been identified as a risk factor for SICH in patients treated with intravenous thrombolytics for acute myocardial infarction [35]. This discrepancy may reflect differing pathophysiology of SICH in patients with myocardial infarction compared to stroke patients or may be the result of increased power to detect risk factors in the larger acute myocardial infarction trials.

Time to Onset of Treatment with Thrombolytic Agent

Only 1 study identified onset of treatment with thrombolytic agent as an independent risk factor of SICH in multivariate analysis [9]. In 1 other study there was an association in univariate but not in multivariate analysis [19]. Also in the pooled analysis of the NINDS, ECASS and ATLANTIS trials no independent association between onset of treatment with thrombolytic agent and risk of substantial intracerebral hemorrhage was shown [6]. Most of the studies reviewed here allowed treatment up to 3 h, whereas only few allowed treatment up to 6 h. Therefore, the risk of SICH at later treatment times is not well established.

Blood Pressure

Only 1 study included in this review found a significant association between blood pressure and SICH [17]. In this study higher systolic blood pressure was an independent predictor of SICH. In 1 additional study systolic blood pressure was significant in univariate but not in multivariate analysis [10]. The risk of SICH associated with uncontrolled severe hypertension is not known because these patients were excluded from all stroke thrombolysis trials and clinical guidelines recommend that such patients are excluded from rt-PA treatment in routine clinical practice [4, 36]. In the Global Use of Strategies to Open Occluded Coronary Arteries trial, which evaluated the effect of thromboysis for acute myocardial infarction, higher blood pressures were associated with an increased risk of SICH [35].

Thrombocytopenia

A very low platelet count (<100,000/μl) is a contraindication for the routine use of rt-PA [3, 36] and thrombolytic trials have generally excluded these patients. Therefore, data are only available on patients with platelet counts exceeding 100,000/μl. Platelet counts were evaluated as a potential independent variable in 4 of the reviewed studies [10, 15, 16, 29,] of which only 1 identified lower platelet counts as an independent risk factor for SICH [10]. In the other 3 studies no association was found in either univariate or multivariate analyses [15, 16, 29].

History of Cardiac Disease

Different definitions for ‘history of cardiac disease’ were used across studies, but they are grouped here under the same paragraph for clarity. History of cardiac disease was independently associated with an increased risk of SICH in only 1 of the reviewed studies [16]. In this study, prior congestive heart failure increased the risk of hemorrhage [16]. In the Multicenter rt-PA Acute Stroke Survey ‘cardiac disease other than atrial fibrillation’ was associated with an increased risk of SICH when only clinical variables were included in the multivariate model but not after adding imaging and laboratory variables [10]. In this and 1 other study, history of atrial fibrillation was associated with an increased risk of SICH in univariate but not in multivariate analysis [10, 12].

Antiplatelet Agents

Concomitant use of antithrombotic agents was prohibited in most thrombolytic stroke studies, but prior treatment with aspirin (ASA) was allowed. ASA use was not found to be an independent predictor of SICH in any of the reviewed studies. Only in 1 study, the Multicenter rt-PA Acute Stroke Survey, was pretreatment with ASA associated with an increased risk of SICH in univariate analysis, but it did not remain a significant predictor in multivariate analysis [10]. In this same study the use of antiplatelet agents other than ASA (primarily ticlopidine) was independently associated with an increased risk of SICH in a model including only clinical variables, but not in a multivariate model that included clinical as well as laboratory and CT variables. In ECASS II both ASA and an rt-PA-by-ASA interaction were associated with an increased risk of any parenchymal hemorrhage but not SICH [16]. Based on this systematic review there is thus no convincing evidence to support an independent association between prior ASA use and thrombolysis-associated SICH. A recent open prospective study of rt-PA treatment also showed no increased risk of symptomatic bleeding in ASA users compared to patients who did not use ASA [37]. Data on the risk of SICH in patients taking newer antiplatelet agents such as clopidogrel are not available. The only study that tested the interaction between thrombolytic and ASA treatment following stroke by random allocation is the Multicenter Acute Stroke Trial-Italy [38]. In this study combination treatment with ASA and streptokinase resulted in an increased death rate compared to streptokinase alone, which was largely attributable to intracranial hemorrhages.

Biochemical Characteristics

Endogenous fibrinolysis inhibitors, which are released in the circulation following cerebral ischemia, may interact with rt-PA and modify its effect. For example, plasminogen activator inhibitor (PAI-1) is the main inhibitor of rt-PA and low levels are associated with increased rt-PA activity [39]. Of 2 recent studies that have evaluated this marker, 1 demonstrated an independent association between low levels of PAI-1 and rt-PA-associated SICH [18], whereas another found no such association [19]. A further study has demonstrated higher recanalization rates in patients with low pretreatment levels of PAI-1 [40].

There are several other biochemical variables that may help predict SICH risk following thrombolysis. Thrombin-activated fibrinolysis inhibitor has been associated with an increased risk of SICH in univariate analysis, but this relationship did not remain significant after adjusting for potential confounders [18]. Matrix metalloproteinases (MMPs) are enzymes involved in remodeling of extracellular matrix [41]. MMP-2 and MMP-9 break down components of the basal lamina around cerebral blood vessels. One study demonstrated that increased MMP-9 levels prior to administration of rt-PA increase the risk of parenchymal hemorrhage in univariate analysis [42]. In a rabbit embolic stroke model, administration of an MMP inhibitor decreased the rate of hemorrhagic transformation following thrombolysis with rt-PA [43]. High cellular fibronectin levels, a substance that reflects microvasculature damage, correlate with MMP-9 levels and also have a strong association with hemorrhagic transformation [44].

MRI Characteristics

None of the studies that examine baseline magnetic resonance imaging (MRI) characteristics and SICH risk following thrombolytic therapy met inclusion criteria for this review. However, because the use of MRI to predict the response to rt-PA has recently received much attention in the scientific literature, a secondary review of this topic is included. In 1 study volume of ischemic tissue on diffusion-weighted MRI, with an apparent diffusion coefficient ≤550 × 10–6 mm2/s, was the single independent predictor of any ICH [29]. One recent preliminary presentation showed that larger diffusion-weighted MRI lesion volume was the single independent predictor of SICH among several clinical and MRI-based variables [45]. Although these data suggest that MRI parameters may help predict SICH risk, future studies are needed to confirm this observation.

Four other MRI variables have been postulated to predict rt-PA-related SICH. First, the degree of hypoperfusion, specifically low cerebral blood volume on perfusion-weighted imaging, has been identified as a potential predictor of SICH [46]. Second, damage to the blood-brain barrier as evidenced by enhancement on postcontrast T1-weighted images appears predictive of hemorrhage both in animal models [47, 48] and in human studies [49, 50]. Third, delayed gadolinium enhancement of cerebrospinal fluid space on fluid-attenuated inversion recovery images, which has been termed hyperintense acute reperfusion marker (HARM), also reflects disruption of the blood-brain barrier and is associated with an increased risk of hemorrhagic transformation [51]. This variable is, however, not a good baseline marker of SICH risk, as it first becomes apparent on delayed MRI. Last, the presence of microbleeds on pretreatment gradient-echo MRI was hypothesized to be a potential risk factor of SICH based on an observation in a single patient in a small case series [52], but 2 subsequent larger studies found no association between microbleeds and SICH [53, 54].

 

Discussion


This report provides a systematic review of risk factors that have been shown to have an independent association with SICH following thrombolytic therapy for acute stroke. The implications of these data are twofold. First, they provide some insight into the pathophysiological mechanisms underlying the development of SICH. SICH following rt-PA is thought to be the result of reperfusion of cerebral vessels whose integrity has been disrupted by severe ischemia [55, 56]. The increased risk of SICH seen in rt-PA-treated patients with extensive early infarct changes on CT is consistent with this hypothesis, as EICs reflect cerebral edema which develops secondary to ischemic injury of the brain parenchyma, a process that is closely linked to ischemic injury of the cerebral microvasculature. Other indicators of severe cerebral ischemia are large infarct volume with low apparent diffusion coefficient values on MRI and high levels of biomarkers that reflect vascular damage. Although these factors have not yet been studied as extensively as early infarct changes on CT, preliminary data suggest that they too may predict subsequent development of SICH. The damaging effect of ischemia to the blood-brain barrier appears to be aggravated in the presence of hyperglycemia. This was also demonstrated in early animal experiments [57] and suggested a decade ago by Broderick et al. [58], based on observations in 2 human stroke cases. The current review supports this concept by demonstrating that hyperglycemia is a risk factor for thrombolysis-associated SICH. Because of the close association between history of diabetes mellitus and serum glucose on admission it is difficult to determine which of these 2 factors more strongly predicts SICH risk. Our review of univariate analyses suggests greater importance of serum glucose than history of diabetes. Conceptually the 2 factors may contribute to an increased risk of SICH via different pathophysiological mechanisms. Chronic microvascular damage secondary to long-standing diabetes may predispose vessels to rupture in the setting of ischemia, whereas biochemical sequelae of hyperglycemia may contribute to acute injury of the blood-brain barrier [57], leading to increased hemorrhage rates [59]. A final factor in the pathophysiology of SICH may be a milieu that enhances the potency of rt-PA. This is exemplified by the finding that low levels of the endogenous occurring rt-PA inhibitor PAI-1 may be associated with an increased risk of SICH. However, because identification of an independent association does not confirm a causal relationship between a risk factor and SICH, inferences regarding potential pathophysiological mechanisms should be viewed with caution.

Second, knowledge of the key risk factors of thrombolysis-associated SICH may lead the way to future stroke trials aimed at improving the efficacy of thrombolysis by reducing the risk of SICH. One example is to compare the routine rt-PA dosing regimen to a regimen that is adjusted based on knowledge of pretreatment levels of fibrinolytic enzymes (such as PAI-1) that modulate the potency of rt-PA. A randomized trial between standard and aggressive serum glucose control in stroke patients who receive rt-PA is another example. Aggressive glucose control may reduce the SICH rate and may also improve the outcome in patients who do not develop SICH [60]. This is suggested by a post hoc analysis of the NINDS tPA trial, which demonstrated a deleterious effect of hyperglycemia on stroke outcome and a decreased chance for neurological improvement even in the absence of SICH [61]. Similar results have been reported by others [62,63,64].

Our review has several limitations. First, it does not address the SICH risk posed by the presence of a combination of risk factors in the same individual. Although the effect may simply be cumulative, there is evidence indicating that the interaction between multiple risk factors may be synergistic. According to 1 study, the calculated chance of SICH in patients without infarct signs on CT is 5% with average glucose levels (150 mg/dl) and 13% with high glucose levels (350 mg/dl), whereas the chance of SICH in patients with infarct signs on CT is 26% with average and 52% with high baseline glucose levels. Second, none of the referenced studies were specifically powered to detect risk factors for thrombolysis-related SICH. This results in a relatively high likelihood of failing to identify a risk factor even though an association exists (high chance of type II error). Type I errors (falsely identifying a variable as a risk factor even though no association exists) may also have been introduced in some of the studies because too many dependent variables were included in the statistical models without correcting for multiple comparisons. Third, in the reviewed studies patients with extreme values of any of the clinical variables were generally excluded (e.g. uncontrolled hypertension, severe hyperglycemia or thrombocytopenia). Our conclusions therefore apply to patients whose clinical parameters fall within the range that is generally felt to be acceptable for intravenous rt-PA treatment according to current guidelines [3, 36]. Fourth, the prespecified inclusion criteria for this review resulted in a fairly homogeneous set of studies, but differences, inherent to any review, are present. These include differences in study size, SICH definition, thrombolytic agent used, route of administration and treatment time window. There may also be factors that are independently associated with an SICH risk but that were not included in the univariate analysis of any of the studies. For example, in the Desmoteplase in Acute Ischemic Stroke trial higher dosing of thrombolytics was associated with unacceptably high rates of SICH (27%), whereas more moderate dosing was not (SICH rate 2.2%), suggesting that dose of thrombolytic is a risk factor for SICH [65].

Different classification schemes for thrombolysis-associated hemorrhage have been used. The most common classification distinguishes symptomatic from asymptomatic hemorrhages. Because of its widespread use and clinical significance the search strategy for this review was based on this classification and included only studies with data on SICH as the outcome variable. This classification may, however, not be optimally suited to determine the pathophysiology of thrombolysis-associated hemorrhage because hemorrhage severity does not correlate strongly with the degree of clinical worsening [66, 67]. A classification based on brain imaging that distinguishes between hemorrhagic infarcts and parenchymal hematomas has been used by the ECASS investigators and may be more useful in this respect [22, 66, 68, 69]. In a recent review, Trouillas and von Kummer [66] conclude that hemorrhagic infarctions, characterized by punctate/petechial lesions within the ischemic infarct, are generally not clinically significant and are not related to thrombolytic therapy, whereas parenchymal hematomas, which are confluent/homogeneous lesions that originate from within the ischemic lesion, are often associated with clinical deterioration and are more common following thrombolytic therapy.

The aim of this study was to provide an up-to-date and comprehensive overview of variables that are likely to be independently associated with risk of SICH following thrombolytic therapy. A systematic review was the most feasible methodology to achieve this aim. Pooled analysis and meta-analysis are alternative methodologies that can be used to study the association between predictor variables and thrombolysis-associated SICH. Although these methodologies provide more quantitative data, several limitations made them inappropriate for achieving the stated aim. These include lack of access to primary data for pooled analysis, inability to evaluate whether risk factors are independently associated with SICH for meta-analysis and lack of data on specific risk factors in many of the studies for both types of analysis. Future studies using meta-analysis to evaluate the association between individual risk factors such as serum glucose and SICH could, however, complement this review.

The data presented in this review should not be used to alter current clinical practice guidelines. On the one hand, rt-PA should not be withheld from patients with ≥1 SICH risk factors, as these patients may still benefit from thrombolytic therapy. This was indirectly addressed in a post hoc analysis of the NINDS t-PA trial data [70]. In this study, despite higher SICH rates, the chance of a favorable outcome was significantly greater in the subgroup of patients with severe symptoms at presentation (NIHSSS >20) and there was a trend towards better outcome in patients with mass effect or edema on baseline CT [70]. On the other hand, variables that are current contraindications for the use of intravenous rt-PA should not be disregarded because they were not identified as independent predictors of SICH in this systematic review. For example, history of recent head trauma is a contraindication for the use of rt-PA [3, 5], but this variable was not evaluated in any of the reviewed studies because patients with significant head trauma were excluded from all thrombolytic stroke trials.

In summary, this systematic review identified extensive early infarct changes on CT, elevated serum glucose or history of diabetes mellitus, symptom severity, older age, low PAI-1 levels, increased time to treatment, high systolic blood pressure, low platelet counts and history of prior congestive heart failure as risk factors for thrombolysis-associated SICH. Future research is required to determine whether any therapeutic interventions can reduce the SICH rate and thereby enhance the effectiveness of rt-PA.

 

Acknowledgment


The funding for this study was provided by NIH grants K23 NS051372, Principal Investigator Maarten G. Lansberg.


References

  1. Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–1587.
  2. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003–2011.
  3. Adams H, Adams R, Del Zoppo G, Goldstein LB: Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update – a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005;36:916–923.
  4. Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ: Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34:1056–1083.
  5. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 (suppl 3):483S–512S.

    External Resources

  6. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick J, Brott T, Frankel M, Grotta J, Haley EC, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers GW, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768–774.
  7. Graham GD: Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003;34:2847–2850.
  8. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Stroke 1997;28:2109–2118.
  9. Hill MD, Buchan AM; for the Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators: Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172:1307–1312.
  10. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, Levine SR: Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002;105:1679–1685.
  11. Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH, Hardy RJ, Grotta JC, Buchan AM: Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999;30:34–39.
  12. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, Hommel M: Hemorrhagic transformation in acute ischemic stroke: the MAST-E study. MAST-E Group. Stroke 1999;30:1326–1332.
  13. Barber PA, Demchuk AM, Zhang J, Buchan AM: Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000;355:1670–1674.
  14. Dubey N, Bakshi R, Wasay M, Dmochowski J: Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke. J Neuroimaging 2001;11:184–188.
  15. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, Molinari GF, Frederick LS, Roberts HC, Gebel JM, Sila CA, Schulz GA, Roberts RS, Gent M: Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology 2001;57:1603–1610.
  16. Larrue V, von Kummer R, Muller A, Bluhmki E: Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438–441.
  17. Gilligan AK, Markus R, Read S, Srikanth V, Hirano T, Fitt G, Arends M, Chambers BR, Davis SM, Donnan GA: Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke 2002;33:2236–2242.
  18. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Quintana M, Alvarez-Sabin J: Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004;35:2123–2127.
  19. Cocho D, Borrell M, Marti-Fabregas J, Montaner J, Castellanos M, Bravo Y, Molina-Porcel L, Belvis R, Diaz-Manera J-A, Martinez-Domeno A, Martinez-Lage M, Millan M, Fontcuberta J, Marti-Vilalta J-L: Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator. Stroke 2006;37:996–999.
  20. Von Kummer R, Holle R, Gizyska U, Hofmann E, Jansen O, Petersen D, Schumacher M, Sartor K: Interobserver agreement in assessing early CT signs of middle cerebral artery infarction. AJNR Am J Neuroradiol 1996;17:1743–1748.
  21. Dzialowski I, Hill MD, Coutts SB, Demchuk AM, Kent DM, Wunderlich O, von Kummer R: Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke 2006;37:973–978.
  22. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025.
  23. Von Kummer R, Allen KL, Holle R, Bozzao L, Bastianello S, Manelfe C, Bluhmki E, Ringleb P, Meier DH, Hacke W: Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology 1997;205:327–333.
  24. Grotta JC, Chiu D, Lu M, Patel S, Levine SR, Tilley BC, Brott TG, Haley EC Jr, Lyden PD, Kothari R, Frankel M, Lewandowski CA, Libman R, Kwiatkowski T, Broderick JP, Marler JR, Corrigan J, Huff S, Mitsias P, Talati S, Tanne D: Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 1999;30:1528–1533.
  25. Marks MP, Holmgren EB, Fox AJ, Patel S, von Kummer R, Froehlich J: Evaluation of early computed tomographic findings in acute ischemic stroke. Stroke 1999;30:389–392.
  26. Dippel DW, Du Ry van Beest Holle M, van Kooten F, Koudstaal PJ: The validity and reliability of signs of early infarction on CT in acute ischaemic stroke. Neuroradiology 2000;42:629–633.
  27. Schriger DL, Kalafut M, Starkman S, Krueger M, Saver JL: Cranial computed tomography interpretation in acute stroke: physician accuracy in determining eligibility for thrombolytic therapy. JAMA 1998;279:1293–1297.
  28. Wardlaw JM, Dorman PJ, Lewis SC, Sandercock PA: Can stroke physicians and neuroradiologists identify signs of early cerebral infarction on CT? J Neurol Neurosurg Psychiatry 1999;67:651–653.
  29. Selim M, Fink JN, Kumar S, Caplan LR, Horkan C, Chen Y, Linfante I, Schlaug G: Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke 2002;33:2047–2052.
  30. Tong DC, Yenari MA, Albers GW, O’Brien M, Marks MP, Moseley ME: Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (<6.5 h) ischemic stroke. Neurology 1998;50:864–870.
  31. Patel S, Levine S, Tilley BC, et al: Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001;286:2830–2838.
  32. Chen CI, Iquchi Y, Grotta JC, Garami Z, Uchino K, Shaltoni H, Alexandrov AV: Intravenous TPA for very old stroke patients. Eur Neurol 2005;54:140–144.
  33. Sylaja PN, Cote R, Buchan AM, Hill MD; on behalf of Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators: Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006;77:826–829.
  34. Engelter ST, Bonati LH, Lyrer PA: Intravenous thrombolysis in stroke patients of ≥ 80 versus <80 years of age – a systematic review across cohort studies. Age Ageing 2006;35:572–580.
  35. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, et al: Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial – Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995;92:2811–2818.
  36. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119(suppl 1):300S–320S.

    External Resources

  37. Schmulling S, Rudolf J, Strotmann-Tack T, Grond M, Schneweis S, Sobesky J, Thiel A, Heiss WD: Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis 2003;16:183–190.
  38. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke: Multicentre Acute Stroke Trial–Italy (MAST-I) Group. Lancet 1995;346:1509–1514.
  39. Gils A, Declerck PJ: The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004;91:425–437.
  40. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J: Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004;91:1146–1151.
  41. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121–125.
  42. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598–603.
  43. Lapchak PA, Chapman DF, Zivin JA: Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000;31:3034–3040.
  44. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Davalos A: Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004;35:1671–1676.
  45. Lansberg MG, Thijs V, Bammer R, Kakuda W, Hamilton S, Wechsler L, Wijman C, Kemp S, Albers GW: Clinical and MRI-based risk factors for symptomatic intracerebral hemorrhage following treatment with tissue plasminogen activator. Stroke 2006;37:654.

    External Resources

  46. Alsop DC, Makovetskaya E, Kumar S, Selim M, Schlaug G: Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke. Stroke 2005;36:746–750.
  47. Dijkhuizen RM, Asahi M, Wu O, Rosen BR, Lo EH: Delayed rt-PA treatment in a rat embolic stroke model: diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging. J Cereb Blood Flow Metab 2001;21:964–971.
  48. Neumann-Haefelin C, Brinker G, Uhlenkuken U, Pillekamp F, Hossmann K-A, Hoehn M: Prediction of hemorrhagic transformation after thrombolytic therapy of clot embolism: an MRI investigation in rat brain. Stroke 2002;33:1392–1398.
  49. Kim EY, Na DG, Kim SS, Lee KH, Ryoo JW, Kim HK: Prediction of hemorrhagic transformation in acute ischemic stroke: role of diffusion-weighted imaging and early parenchymal enhancement. AJNR Am J Neuroradiol 2005;26:1050–1055.
  50. Vo KD, Santiago F, Lin W, Hsu CY, Lee Y, Lee JM: MR imaging enhancement patterns as predictors of hemorrhagic transformation in acute ischemic stroke. AJNR Am J Neuroradiol 2003;24:674–679.
  51. Warach S, Latour LL: Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke 2004;35(suppl 1):2659–2661.

    External Resources

  52. Kidwell CS, Saver JL, Carneado J, Sayre J, Starkman S, Duckwiler G, Gobin YP, Jahan R, Vespa P, Villablanca JP, Liebeskind DS, Vinuela F: Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002;33:717–724.
  53. Kakuda W, Thijs VN, Lansberg MG, Bammer R, Wechsler L, Kemp S, Moseley ME, Marks MP, Albers GW; for the DEFUSE investigators: Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology 2005;65:1175–1178.
  54. Derex L, Nighoghossian N, Hermier M, Adeleine P, Philippeau F, Honnorat J, Yilmaz H, Dardel P, Froment JC, Trouillas P: Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis 2004;17:238–241.
  55. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH: Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004;35(suppl 1):2726– 2730.
  56. Maier CM, Hsieh L, Crandall T, Narasimhan P, Chan PH: Evaluating therapeutic targets for reperfusion-related brain hemorrhage. Ann Neurol 2006;59:929–938.
  57. Dietrich W, Alonso O, Busto R: Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. Stroke 1993;24:111–116.
  58. Broderick JP, Hagen T, Brott T, Tomsick T: Hyperglycemia and hemorrhagic transformation of cerebral infarcts. Stroke 1995;26:484–487.
  59. Kawai N, Keep RF, Betz AL, Dietrich WD: Hyperglycemia and the vascular effects of cerebral ischemia. Stroke 1997;28:149–154.
  60. Levetan CS: Effect of hyperglycemia on stroke outcomes. Endocr Pract 2004;10 (suppl 2):34–39.

    External Resources

  61. Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE: Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002;59:669–674.
  62. Leigh R, Zaidat OO, Suri MF, Lynch G, Sundararajan S, Sunshine JL, Tarr R, Selman W, Landis DMD, Suarez JI: Predictors of hyperacute clinical worsening in ischemic stroke patients receiving thrombolytic therapy. Stroke 2004;35:1903–1907.
  63. Alvarez-Sabin J, Molina CA, Montaner J, Arenillas JF, Huertas R, Ribo M, Codina A, Quintana M: Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator-treated patients. Stroke 2003;34:1235–1240.
  64. Engelter ST, Reichhart M, Sekoranja L, Georgiadis D, Baumann A, Weder B, Muller F, Luthy R, Arnold M, Michel P, Mattle HP, Tettenborn B, Hungerbuhler HJ, Baumgartner RW, Sztajzel R, Bogousslavsky J, Lyrer PA: Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 2005;65:1795–1798.
  65. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; for the DIAS Study Group: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase ii mri-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66–73.
  66. Trouillas P, von Kummer R: Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006;37:556–561.
  67. Von Kummer R: Brain hemorrhage after thrombolysis: good or bad? Stroke 2002;33:1446–1447.
  68. Pessin MS, Del Zoppo GJ, Estol CJ: Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 1990;13:271–289.
  69. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245–1251.
  70. Generalized Efficacy of t-PA for Acute Stroke: Subgroup Analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119–2125.

  

Author Contacts

Maarten G. Lansberg, MD
Stanford University, Stanford Stroke Center
701 Welch Road, Suite B
Palo Alto, CA 94304 (USA)
Tel. +1 650 723 4448, Fax +1 650 723 4451, E-Mail Lansberg@stanford.edu

  

Article Information

Received: September 29, 2006
Accepted: December 21, 2006
Published online: May 22, 2007
Number of Print Pages : 10
Number of Figures : 0, Number of Tables : 2, Number of References : 70

  

Publication Details

Cerebrovascular Diseases

Vol. 24, No. 1, Year 2007 (Cover Date: June 2007)

Journal Editor: Hennerici, M.G. (Mannheim)
ISSN: 1015–9770 (print), 1421–9786 (Online)

For additional information: http://www.karger.com/CED


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Abstract

Background: Symptomatic intracerebral hemorrhage (SICH) following thrombolytic therapy for acute ischemic stroke is associated with a high rate of morbidity and mortality. Knowledge of the risk factors associated with SICH following thrombolyitc therapy may provide insight into the pathophysiological mechanisms underlying the development of SICH, lead to the development of treatments that reduce the risk of SICH and have implications for the design of future stroke trials. Methods: Relevant studies were identified through a search in Pubmed. Included studies used multivariate analyses to identify independent risk factors for SICH following thrombolytic therapy. For each variable that was found to have a significant association with SICH, a secondary literature search was conducted to identify additional reports on the specific relationship between that variable and SICH. Summary of Review: Twelve studies met inclusion criteria for the systematic review. Extent of hypoattenuated brain parenchyma on pretreatment CT and elevated serum glucose or history of diabetes were independent risk factors for thrombolysis-associated SICH in six of the twelve studies. Symptom severity was an independent risk factor in three of the studies and advanced age, increased time to treatment, high systolic blood pressure, low platelets, history of congestive heart failure and low plasminogen activator inhibitor levels were found to be independent risk factors for SICH in a single study. Although these data should not alter the current guidelines for the use of rt-PA in acute stroke, they may help develop future strategies aimed at reducing the rate of thrombolysis-associated SICH.

© 2007 S. Karger AG, Basel


  

Author Contacts

Maarten G. Lansberg, MD
Stanford University, Stanford Stroke Center
701 Welch Road, Suite B
Palo Alto, CA 94304 (USA)
Tel. +1 650 723 4448, Fax +1 650 723 4451, E-Mail Lansberg@stanford.edu

  

Article Information

Received: September 29, 2006
Accepted: December 21, 2006
Published online: May 22, 2007
Number of Print Pages : 10
Number of Figures : 0, Number of Tables : 2, Number of References : 70

  

Publication Details

Cerebrovascular Diseases

Vol. 24, No. 1, Year 2007 (Cover Date: June 2007)

Journal Editor: Hennerici, M.G. (Mannheim)
ISSN: 1015–9770 (print), 1421–9786 (Online)

For additional information: http://www.karger.com/CED


Article / Publication Details

First-Page Preview
Abstract of Review

Received: 9/29/2006
Accepted: 12/21/2006
Published online: 5/22/2007
Issue release date: June 2007

Number of Print Pages: 10
Number of Figures: 0
Number of Tables: 2

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: http://www.karger.com/CED


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–1587.
  2. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999;282:2003–2011.
  3. Adams H, Adams R, Del Zoppo G, Goldstein LB: Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update – a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005;36:916–923.
  4. Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ: Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34:1056–1083.
  5. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 (suppl 3):483S–512S.

    External Resources

  6. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick J, Brott T, Frankel M, Grotta J, Haley EC, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers GW, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768–774.
  7. Graham GD: Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003;34:2847–2850.
  8. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Stroke 1997;28:2109–2118.
  9. Hill MD, Buchan AM; for the Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators: Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172:1307–1312.
  10. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, Levine SR: Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002;105:1679–1685.
  11. Demchuk AM, Morgenstern LB, Krieger DW, Linda Chi T, Hu W, Wein TH, Hardy RJ, Grotta JC, Buchan AM: Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999;30:34–39.
  12. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, Hommel M: Hemorrhagic transformation in acute ischemic stroke: the MAST-E study. MAST-E Group. Stroke 1999;30:1326–1332.
  13. Barber PA, Demchuk AM, Zhang J, Buchan AM: Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000;355:1670–1674.
  14. Dubey N, Bakshi R, Wasay M, Dmochowski J: Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke. J Neuroimaging 2001;11:184–188.
  15. Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, Molinari GF, Frederick LS, Roberts HC, Gebel JM, Sila CA, Schulz GA, Roberts RS, Gent M: Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology 2001;57:1603–1610.
  16. Larrue V, von Kummer R, Muller A, Bluhmki E: Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438–441.
  17. Gilligan AK, Markus R, Read S, Srikanth V, Hirano T, Fitt G, Arends M, Chambers BR, Davis SM, Donnan GA: Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke 2002;33:2236–2242.
  18. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Quintana M, Alvarez-Sabin J: Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004;35:2123–2127.
  19. Cocho D, Borrell M, Marti-Fabregas J, Montaner J, Castellanos M, Bravo Y, Molina-Porcel L, Belvis R, Diaz-Manera J-A, Martinez-Domeno A, Martinez-Lage M, Millan M, Fontcuberta J, Marti-Vilalta J-L: Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator. Stroke 2006;37:996–999.
  20. Von Kummer R, Holle R, Gizyska U, Hofmann E, Jansen O, Petersen D, Schumacher M, Sartor K: Interobserver agreement in assessing early CT signs of middle cerebral artery infarction. AJNR Am J Neuroradiol 1996;17:1743–1748.
  21. Dzialowski I, Hill MD, Coutts SB, Demchuk AM, Kent DM, Wunderlich O, von Kummer R: Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke 2006;37:973–978.
  22. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025.
  23. Von Kummer R, Allen KL, Holle R, Bozzao L, Bastianello S, Manelfe C, Bluhmki E, Ringleb P, Meier DH, Hacke W: Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology 1997;205:327–333.
  24. Grotta JC, Chiu D, Lu M, Patel S, Levine SR, Tilley BC, Brott TG, Haley EC Jr, Lyden PD, Kothari R, Frankel M, Lewandowski CA, Libman R, Kwiatkowski T, Broderick JP, Marler JR, Corrigan J, Huff S, Mitsias P, Talati S, Tanne D: Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 1999;30:1528–1533.
  25. Marks MP, Holmgren EB, Fox AJ, Patel S, von Kummer R, Froehlich J: Evaluation of early computed tomographic findings in acute ischemic stroke. Stroke 1999;30:389–392.
  26. Dippel DW, Du Ry van Beest Holle M, van Kooten F, Koudstaal PJ: The validity and reliability of signs of early infarction on CT in acute ischaemic stroke. Neuroradiology 2000;42:629–633.
  27. Schriger DL, Kalafut M, Starkman S, Krueger M, Saver JL: Cranial computed tomography interpretation in acute stroke: physician accuracy in determining eligibility for thrombolytic therapy. JAMA 1998;279:1293–1297.
  28. Wardlaw JM, Dorman PJ, Lewis SC, Sandercock PA: Can stroke physicians and neuroradiologists identify signs of early cerebral infarction on CT? J Neurol Neurosurg Psychiatry 1999;67:651–653.
  29. Selim M, Fink JN, Kumar S, Caplan LR, Horkan C, Chen Y, Linfante I, Schlaug G: Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke 2002;33:2047–2052.
  30. Tong DC, Yenari MA, Albers GW, O’Brien M, Marks MP, Moseley ME: Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (<6.5 h) ischemic stroke. Neurology 1998;50:864–870.
  31. Patel S, Levine S, Tilley BC, et al: Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001;286:2830–2838.
  32. Chen CI, Iquchi Y, Grotta JC, Garami Z, Uchino K, Shaltoni H, Alexandrov AV: Intravenous TPA for very old stroke patients. Eur Neurol 2005;54:140–144.
  33. Sylaja PN, Cote R, Buchan AM, Hill MD; on behalf of Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators: Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006;77:826–829.
  34. Engelter ST, Bonati LH, Lyrer PA: Intravenous thrombolysis in stroke patients of ≥ 80 versus <80 years of age – a systematic review across cohort studies. Age Ageing 2006;35:572–580.
  35. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, et al: Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I trial – Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995;92:2811–2818.
  36. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001;119(suppl 1):300S–320S.

    External Resources

  37. Schmulling S, Rudolf J, Strotmann-Tack T, Grond M, Schneweis S, Sobesky J, Thiel A, Heiss WD: Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis 2003;16:183–190.
  38. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke: Multicentre Acute Stroke Trial–Italy (MAST-I) Group. Lancet 1995;346:1509–1514.
  39. Gils A, Declerck PJ: The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004;91:425–437.
  40. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J: Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004;91:1146–1151.
  41. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121–125.
  42. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598–603.
  43. Lapchak PA, Chapman DF, Zivin JA: Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000;31:3034–3040.
  44. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Davalos A: Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004;35:1671–1676.
  45. Lansberg MG, Thijs V, Bammer R, Kakuda W, Hamilton S, Wechsler L, Wijman C, Kemp S, Albers GW: Clinical and MRI-based risk factors for symptomatic intracerebral hemorrhage following treatment with tissue plasminogen activator. Stroke 2006;37:654.

    External Resources

  46. Alsop DC, Makovetskaya E, Kumar S, Selim M, Schlaug G: Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke. Stroke 2005;36:746–750.
  47. Dijkhuizen RM, Asahi M, Wu O, Rosen BR, Lo EH: Delayed rt-PA treatment in a rat embolic stroke model: diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging. J Cereb Blood Flow Metab 2001;21:964–971.
  48. Neumann-Haefelin C, Brinker G, Uhlenkuken U, Pillekamp F, Hossmann K-A, Hoehn M: Prediction of hemorrhagic transformation after thrombolytic therapy of clot embolism: an MRI investigation in rat brain. Stroke 2002;33:1392–1398.
  49. Kim EY, Na DG, Kim SS, Lee KH, Ryoo JW, Kim HK: Prediction of hemorrhagic transformation in acute ischemic stroke: role of diffusion-weighted imaging and early parenchymal enhancement. AJNR Am J Neuroradiol 2005;26:1050–1055.
  50. Vo KD, Santiago F, Lin W, Hsu CY, Lee Y, Lee JM: MR imaging enhancement patterns as predictors of hemorrhagic transformation in acute ischemic stroke. AJNR Am J Neuroradiol 2003;24:674–679.
  51. Warach S, Latour LL: Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke 2004;35(suppl 1):2659–2661.

    External Resources

  52. Kidwell CS, Saver JL, Carneado J, Sayre J, Starkman S, Duckwiler G, Gobin YP, Jahan R, Vespa P, Villablanca JP, Liebeskind DS, Vinuela F: Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002;33:717–724.
  53. Kakuda W, Thijs VN, Lansberg MG, Bammer R, Wechsler L, Kemp S, Moseley ME, Marks MP, Albers GW; for the DEFUSE investigators: Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology 2005;65:1175–1178.
  54. Derex L, Nighoghossian N, Hermier M, Adeleine P, Philippeau F, Honnorat J, Yilmaz H, Dardel P, Froment JC, Trouillas P: Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis 2004;17:238–241.
  55. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH: Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004;35(suppl 1):2726– 2730.
  56. Maier CM, Hsieh L, Crandall T, Narasimhan P, Chan PH: Evaluating therapeutic targets for reperfusion-related brain hemorrhage. Ann Neurol 2006;59:929–938.
  57. Dietrich W, Alonso O, Busto R: Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. Stroke 1993;24:111–116.
  58. Broderick JP, Hagen T, Brott T, Tomsick T: Hyperglycemia and hemorrhagic transformation of cerebral infarcts. Stroke 1995;26:484–487.
  59. Kawai N, Keep RF, Betz AL, Dietrich WD: Hyperglycemia and the vascular effects of cerebral ischemia. Stroke 1997;28:149–154.
  60. Levetan CS: Effect of hyperglycemia on stroke outcomes. Endocr Pract 2004;10 (suppl 2):34–39.

    External Resources

  61. Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE: Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 2002;59:669–674.
  62. Leigh R, Zaidat OO, Suri MF, Lynch G, Sundararajan S, Sunshine JL, Tarr R, Selman W, Landis DMD, Suarez JI: Predictors of hyperacute clinical worsening in ischemic stroke patients receiving thrombolytic therapy. Stroke 2004;35:1903–1907.
  63. Alvarez-Sabin J, Molina CA, Montaner J, Arenillas JF, Huertas R, Ribo M, Codina A, Quintana M: Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator-treated patients. Stroke 2003;34:1235–1240.
  64. Engelter ST, Reichhart M, Sekoranja L, Georgiadis D, Baumann A, Weder B, Muller F, Luthy R, Arnold M, Michel P, Mattle HP, Tettenborn B, Hungerbuhler HJ, Baumgartner RW, Sztajzel R, Bogousslavsky J, Lyrer PA: Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 2005;65:1795–1798.
  65. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; for the DIAS Study Group: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase ii mri-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66–73.
  66. Trouillas P, von Kummer R: Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006;37:556–561.
  67. Von Kummer R: Brain hemorrhage after thrombolysis: good or bad? Stroke 2002;33:1446–1447.
  68. Pessin MS, Del Zoppo GJ, Estol CJ: Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 1990;13:271–289.
  69. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245–1251.
  70. Generalized Efficacy of t-PA for Acute Stroke: Subgroup Analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119–2125.